# Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes

> **NCT03235973** · PHASE1 · UNKNOWN · sponsor: **Institut Paoli-Calmettes** · enrollment: 29 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute
- Leukemia, Lymphoblastic, Acute

## Interventions

- **DRUG:** Fludarabine-Cladribine-Busulfan conditioning regimen

## Key facts

- **NCT ID:** NCT03235973
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-28
- **Primary completion:** 2020-04
- **Final completion:** 2021-04
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2018-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235973, "Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03235973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*